Skip To Main Content
Mylestone Monna on Muck Rack

Mylestone Monna

As seen in: UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mylestone

Contact Mylestone, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.

|
By David Hennes, Abdullah Al-Khanaty, Mylestone Monna
| UroToday Verified
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is now an established treatment for metastatic castration-resistant prostate cancer (mCRPC), demonstrating improved oncologic outcomes and incorporation into international guidelines. Landmark trials including VISION, TheraP, and PSMAfore have defined the efficacy, safety, and clinical role of [177Lu] Lu-PSMA-617, showing improvements in survival, progression-free survival, and biochemical response rates.
Open in Who Shared Issue with article?
See all 1 articles